Ex vivo tumor analysis revealed a significant reduction in CD8a+ T cells by day 3 post-EBRT, with the percentage area of CD8a+ T cells decreasing to 0.20 ± 0.17 %, compared to 0.91 ± 0.31 % in the CT-only control (P = 0.0126, Fig. 4b-c). Here, CD8A is linked to neoplasm.